Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) have been given a consensus rating of “Moderate Buy” by the five brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $11.25.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Evaxion A/S in a report on Tuesday, October 6th.

Evaxion A/S Stock Up 4.0%

EVAX opened at $2.86 on Wednesday. Evaxion A/S has a 52 week low of $2.67 and a 52 week high of $6.92. The business has a 50 day moving average price of $3.14 and a two-hundred day moving average price of $3.45. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.69. The company has a market cap of $25.80 million, a PE ratio of -2.36 and a beta of 0.60.

Hedge Funds Weigh In On Evaxion A/S

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Rathbones Group PLC purchased a new position in Evaxion A/S in the 1st quarter valued at $170,000. Renaissance Technologies LLC acquired a new position in Evaxion A/S in the 1st quarter valued at $146,000. Finally, Annis Gardner Whiting Capital Advisors LLC purchased a new position in Evaxion A/S during the 1st quarter worth $112,000. 11.04% of the stock is currently owned by hedge funds and other institutional investors.

About Evaxion A/S

Evaxion A/S is a Denmark-based biotechnology company that uses artificial intelligence to develop novel immunotherapies and vaccines. Its proprietary AI-Immunology platform is designed to analyze biological data, identify disease-specific targets and support the development of treatments tailored to individual patients or pathogens. The company’s research and development activities focus primarily on personalized cancer vaccines and vaccines for infectious diseases. Evaxion’s pipeline has included programs intended to stimulate the immune system to recognize and attack cancer cells, as well as vaccine candidates targeting bacterial and viral infections.